De-Risking Phase 3 Rheumatoid Arthritis Trials with Model-Based Meta-Analysis (MBMA)
Learn how Model-based meta-analysis (MBMA) helped optimize Phase 3 trial design, dose selection, and development…
Danielle PillsburyAugust 28, 2026
The five drug development questions that bring sponsors to pharmacometrics
Sponsors rarely come to pharmacometrics because they need a model. They come with a development…
Rik de GreefAugust 24, 2026
Beyond Trial and Error: Model-Informed Formulation Development in Practice
Learn how model-informed formulation development and PBPK modeling can guide formulation strategy, bioequivalence, and biowaiver…
Siri Kalyan ChirumamillaAugust 24, 2026
Model-Based Meta-Analysis (MBMA): Real-World Examples
See real-world examples of how model-based meta-analysis (MBMA) uses existing clinical evidence to predict trial…
CertaraAugust 24, 2026
How to Choose Your First-in-Human Dose Approach
MABEL, PK/PD, mPAD, PBPK, or QSP? Certara scientists on matching your first-in-human dose prediction approach…
CertaraAugust 17, 2026
MBMA data curation: How AI and expert meta-analysts get it right, fast
In MBMA, the data layer is the real bottleneck. See how AI and expert meta-analysts…
Matt Zierhut, PhD MBAAugust 14, 2026
A model-informed approach to radioligand therapy dosing under Project Optimus
Explore how targeted radionuclide therapy dosing uses QSP, biologically effective dose (BED), and exposure-response modeling…
Hunter Stephens, PhDAugust 13, 2026
Managing drug-drug interaction (DDI) risk for patients in clinical trials
Discover how DIDB® helps clinical teams assess drug-drug interaction risk, develop prohibited medication lists, &…
Katie Owens, PhDAugust 12, 2026
Investor panel: What it takes to build a fundable biotech – with Life Science Nation
Investors, founders, and drug development strategists on what makes an early-stage biotech investable beyond the…
CertaraAugust 6, 2026
